An Oruka Therapeutics (ORKA) Insider Sold 105,000 Shares Worth $6.2 Million

Carl Dambkowski, Director of Oruka Therapeutics, sold 105,000 shares worth approximately $6.19 million on May 21, 2026, reducing his direct holdings by 58.74%. Despite the significant sale, Dambkowski retains approximately 73,743 shares and derivative securities. The sale was executed through the exercise and immediate sale of vested options. Oruka, a clinical-stage biotech company developing monoclonal antibody therapeutics, has seen its stock surge 407% over the past 12 months following positive clinical trial results for its lead candidate ORKA-001 in psoriasis treatment.